Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
See All Experts
featured
Published in Oncology and
1 other channel

Expert Opinion / Interview · July 21, 2016

Immunotherapy in RCC: An Overview of Key New Data From ASCO, Part 2

Farzanna Haffizulla MD, FACP, FAMWA
Eric Jonasch MD
Interview with
Eric Jonasch MD

 

 Save  Recommend
 Share

Additional Info

  1. Haas NB, Puligandla M, McDermott DF, et al. ECOG 1808: Randomized phase II trial of sunitinib with or without gemcitabine in advanced kidney cancer with sarcomatoid features. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 4511.

Disclosure statements are available on the authors' profiles:

Eric Jonasch MD

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading

Most Watched This Week

Related Videos